Tissue and Organ Transplantation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Tissue And Organ Transplantation Market is projected to expand from USD 18.62 Billion in 2025 to USD 31.07 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 8.91%. This sector covers medical interventions where biological tissues or organs are transferred from a donor to a recipient to restore physiological function following organ failure. The market's upward trajectory is primarily driven by the rising global incidence of chronic ailments, including cardiovascular and renal diseases, which create a substantial need for replacement therapies. Furthermore, growth is reinforced by enhancements in medical infrastructure and the development of more effective immunosuppressive regimens, which collectively improve survival rates and long-term patient health post-surgery.

Despite these advancements, the industry confronts a major obstacle in the form of a severe scarcity of donor organs compared to the expanding waiting lists. This imbalance creates a significant bottleneck that strictly limits the number of procedures that can be conducted each year, even amidst high clinical necessity. Data from the Global Observatory on Donation and Transplantation indicates that in 2024, a total of 172,397 solid organ transplants were performed worldwide. This figure emphasizes the persistent difficulty posed by supply limitations in satisfying the growing international demand for transplant surgeries.

Market Drivers

Technological innovations in surgical methods and organ preservation act as a central catalyst for market expansion, notably by prolonging the viability of donor organs outside the human body. Advanced techniques, such as normothermic machine perfusion, enable organs to maintain functionality during transport, which minimizes ischemic damage and allows for the utilization of organs that were previously considered marginal. This transition from static cold storage to dynamic preservation systems increases utilization rates and facilitates complex logistical operations. For instance, TransMedics Group, Inc. reported in their 'Third Quarter 2024 Financial Results' from October 2024 that net revenue reached $108.8 million, a significant increase driven by the rising clinical adoption of their proprietary Organ Care System for lung, heart, and liver programs.

The rising prevalence of chronic conditions, specifically end-stage renal disease and liver failure, continues to heighten the urgent need for biological replacement therapies. Factors such as aging populations, lifestyle choices, and the increasing burden of hypertension and diabetes are quickening the pace at which patients develop terminal organ dysfunction, requiring immediate transplantation.

This enduring disparity between the availability of donor grafts and the number of patients needing treatment places immense pressure on healthcare systems to improve procurement efforts. According to the Health Resources and Services Administration's 'Organ Donation Statistics' from March 2024, over 103,000 candidates were on the national transplant waiting list, illustrating the backlog of chronic organ failure patients. Additionally, the United Network for Organ Sharing noted in 2024 that the U.S. reached a milestone by conducting over 46,000 transplants in the prior year, signaling strong efforts to meet this escalating clinical demand.

Market Challenges

The severe insufficiency of available donor organs acts as a fundamental restriction on the growth potential of the tissue and organ transplantation market. This scarcity imposes a hard limit on the number of procedures that can be performed, which directly curtails the revenue opportunities for medical device manufacturers and transplant centers. Even with advanced surgical infrastructure and high clinical demand, the market struggles to scale efficiently because the necessary biological materials for surgeries are not available in adequate numbers. This gap between supply and demand causes a forced stagnation in procedural growth, leaving a substantial segment of the eligible patient population without necessary care.

The scale of this bottleneck is underscored by recent statistics from major transplant networks, which reveal the stark contrast between resource availability and clinical necessity. According to data from the Organ Procurement and Transplantation Network in 2024, there were over 103,000 candidates registered on the national transplant waiting list in the United States. This figure illustrates that the requirement for transplant interventions vastly outstrips the existing supply, mechanically preventing the market from expanding to satisfy the actual population needs. Consequently, the industry encounters a permanent cap on its operational capacity, hindering the generation of potential revenue that would otherwise result from these life-saving operations.

Market Trends

The emergence of xenotransplantation involving genetically engineered organs is creating a novel source of graftable tissues to mitigate the severe donor shortage. Biotechnology firms are deploying gene-editing technologies to alter porcine organs, removing antigens that trigger rejection and incorporating human regulators to guarantee biocompatibility. This progress steers transplantation away from sole reliance on human donors, presenting a scalable alternative for patients who otherwise face high mortality risks while waiting. As reported by eGenesis in February 2025 within their update 'eGenesis Announces Second Patient Successfully Transplanted with Genetically Engineered Porcine Kidney,' the company successfully performed its second human transplant using a gene-edited kidney, validating the clinical feasibility of this non-human source.

Concurrently, the transition toward minimally invasive and robotic-assisted transplant surgeries is refining procedural accuracy and enhancing post-operative recovery. The adoption of sophisticated robotic platforms enables surgeons to execute intricate vascular anastomoses with greater dexterity than open methods, thereby reducing hospital stays and minimizing complications. This technological advancement not only improves clinical results but also extends surgical eligibility to high-risk patients who were previously considered unsuitable for traditional procedures. According to the 'Intuitive Announces Preliminary Fourth Quarter and Full Year 2024 Results' report by Intuitive Surgical in January 2025, global procedures utilizing da Vinci surgical systems increased by roughly 17% in 2024, underscoring the rapid integration of these platforms into complex medical treatments.

Key Players Profiled in the Tissue And Organ Transplantation Market

• Artivion, Inc.
• Folio Biosciences LLC
• Arthrex, Inc.
• Abbvie Inc.
• Zimmer Biomet Holdings, Inc.
• India Medtronic Private Limited
• Novartis AG
• Stryker Corporation
• BiolifeSolutions Inc.
• Teva Pharmaceutical Industries Ltd.

Report Scope

In this report, the Global Tissue And Organ Transplantation Market has been segmented into the following categories:

Tissue And Organ Transplantation Market, by Product:

• Tissue Products
• Preservation Solutions
• Immunosuppressive Drugs

Tissue And Organ Transplantation Market, by Application:

• Organ Transplantation
• Tissue Transplantation

Tissue And Organ Transplantation Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tissue And Organ Transplantation Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.